NASDAQ:NURO NeuroMetrix (NURO) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free NURO Stock Alerts $4.41 +0.08 (+1.85%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$4.21▼$4.5650-Day Range$2.94▼$4.5752-Week Range$2.70▼$11.55Volume7,135 shsAverage Volume43,024 shsMarket Capitalization$8.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get NeuroMetrix alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About NeuroMetrix Stock (NASDAQ:NURO)NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More NURO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURO Stock News HeadlinesApril 24, 2024 | finance.yahoo.comNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearApril 20, 2024 | investing.comNeuroMetrix appoints new board director, ends ATM facilityApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 19, 2024 | markets.businessinsider.comNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsApril 19, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 19, 2024 | globenewswire.comNeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 18, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comMarch 14, 2024 | globenewswire.comNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaMarch 13, 2024 | globenewswire.comNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaMarch 8, 2024 | finanznachrichten.deRS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.March 8, 2024 | finance.yahoo.comRS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.February 25, 2024 | au.lifestyle.yahoo.comGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesFebruary 24, 2024 | finance.yahoo.comNeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)February 23, 2024 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | finance.yahoo.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | globenewswire.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 15, 2024 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 15, 2024 | globenewswire.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueFebruary 13, 2024 | markets.businessinsider.comNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsFebruary 13, 2024 | finance.yahoo.comNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueJanuary 8, 2024 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024December 12, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID)December 12, 2023 | finance.yahoo.comNeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)See More Headlines Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/25/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NURO CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees26Year Founded1996Profitability EPS (Most Recent Fiscal Year)($6.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,530,000.00 Net Margins-110.64% Pretax Margin-110.64% Return on Equity-31.31% Return on Assets-29.32% Debt Debt-to-Equity RatioN/A Current Ratio16.80 Quick Ratio15.55 Sales & Book Value Annual Sales$5.90 million Price / Sales1.42 Cash FlowN/A Price / Cash FlowN/A Book Value$13.18 per share Price / Book0.32Miscellaneous Outstanding Shares1,990,000Free Float1,842,000Market Cap$8.38 million OptionableNot Optionable Beta2.26 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Shai N. Gozani M.D. (Age 59)Ph.D., Founder, Chairman, CEO, President & Secretary Comp: $444.05kMr. Thomas T. Higgins (Age 72)Senior VP, CFO & Treasurer Comp: $347.75kDr. Xuan Kong Ph.D.Chief Data ScientistMs. Susan M. Bell R.N.Senior Vice President of Population Health & Value Based CareKey CompetitorsIntelligent Bio SolutionsNASDAQ:INBSVapothermNYSE:VAPOVivos TherapeuticsNASDAQ:VVOSPlus TherapeuticsNASDAQ:PSTVAvingerNASDAQ:AVGRView All CompetitorsInstitutional OwnershipCerity Partners LLCBought 30,000 shares on 1/26/2024Ownership: 2.804%View All Institutional Transactions NURO Stock Analysis - Frequently Asked Questions How have NURO shares performed in 2024? NeuroMetrix's stock was trading at $3.60 at the start of the year. Since then, NURO stock has increased by 16.9% and is now trading at $4.21. View the best growth stocks for 2024 here. Are investors shorting NeuroMetrix? NeuroMetrix saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 1,200 shares, a decline of 89.4% from the March 31st total of 11,300 shares. Based on an average daily trading volume, of 48,700 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.1% of the shares of the company are short sold. View NeuroMetrix's Short Interest. When is NeuroMetrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NURO earnings forecast. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings data on Thursday, February, 22nd. The medical device company reported ($1.43) earnings per share for the quarter. The medical device company earned $1.32 million during the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 31.31% and a negative net margin of 110.64%. When did NeuroMetrix's stock split? Shares of NeuroMetrix reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What is Shai N. Gozani's approval rating as NeuroMetrix's CEO? 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Advanced Micro Devices (AMD) and Vaxart (VXRT). How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NURO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
